DK2208794T3 - Fremgangsmåde og kit til kvantificering af lille, tæt LDL-kolesterol - Google Patents
Fremgangsmåde og kit til kvantificering af lille, tæt LDL-kolesterol Download PDFInfo
- Publication number
- DK2208794T3 DK2208794T3 DK08837388.1T DK08837388T DK2208794T3 DK 2208794 T3 DK2208794 T3 DK 2208794T3 DK 08837388 T DK08837388 T DK 08837388T DK 2208794 T3 DK2208794 T3 DK 2208794T3
- Authority
- DK
- Denmark
- Prior art keywords
- ldl
- cholesterol
- polyoxyethylene
- small
- ether
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 121
- 238000008214 LDL Cholesterol Methods 0.000 title claims description 64
- 238000011002 quantification Methods 0.000 title 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 328
- 235000012000 cholesterol Nutrition 0.000 claims description 164
- 239000003153 chemical reaction reagent Substances 0.000 claims description 154
- 238000006243 chemical reaction Methods 0.000 claims description 128
- 239000004094 surface-active agent Substances 0.000 claims description 100
- 239000000203 mixture Substances 0.000 claims description 98
- -1 polyoxyethylene nonylphenyl ether Polymers 0.000 claims description 98
- 102000004895 Lipoproteins Human genes 0.000 claims description 95
- 108090001030 Lipoproteins Proteins 0.000 claims description 95
- 238000005259 measurement Methods 0.000 claims description 54
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 53
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 31
- 102000004190 Enzymes Human genes 0.000 claims description 30
- 108090000790 Enzymes Proteins 0.000 claims description 30
- 108010055297 Sterol Esterase Proteins 0.000 claims description 28
- 102000000019 Sterol Esterase Human genes 0.000 claims description 28
- 108010089254 Cholesterol oxidase Proteins 0.000 claims description 18
- 108010061312 Sphingomyelin Phosphodiesterase Proteins 0.000 claims description 17
- 102000011971 Sphingomyelin Phosphodiesterase Human genes 0.000 claims description 17
- RLFWWDJHLFCNIJ-UHFFFAOYSA-N 4-aminoantipyrine Chemical compound CN1C(C)=C(N)C(=O)N1C1=CC=CC=C1 RLFWWDJHLFCNIJ-UHFFFAOYSA-N 0.000 claims description 14
- 102000016938 Catalase Human genes 0.000 claims description 12
- 108010053835 Catalase Proteins 0.000 claims description 12
- 150000005215 alkyl ethers Chemical class 0.000 claims description 10
- 125000000217 alkyl group Chemical group 0.000 claims description 10
- 102000003992 Peroxidases Human genes 0.000 claims description 9
- DVEKCXOJTLDBFE-UHFFFAOYSA-N n-dodecyl-n,n-dimethylglycinate Chemical compound CCCCCCCCCCCC[N+](C)(C)CC([O-])=O DVEKCXOJTLDBFE-UHFFFAOYSA-N 0.000 claims description 9
- 108040007629 peroxidase activity proteins Proteins 0.000 claims description 9
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 8
- 150000003973 alkyl amines Chemical class 0.000 claims description 8
- 239000003945 anionic surfactant Substances 0.000 claims description 8
- 239000003093 cationic surfactant Substances 0.000 claims description 8
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 7
- 150000008051 alkyl sulfates Chemical class 0.000 claims description 7
- 150000001408 amides Chemical class 0.000 claims description 7
- 239000002280 amphoteric surfactant Substances 0.000 claims description 7
- 229940094506 lauryl betaine Drugs 0.000 claims description 7
- 239000002736 nonionic surfactant Substances 0.000 claims description 7
- 150000003242 quaternary ammonium salts Chemical class 0.000 claims description 7
- 239000011734 sodium Substances 0.000 claims description 7
- 229910052708 sodium Inorganic materials 0.000 claims description 7
- 229940104261 taurate Drugs 0.000 claims description 7
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 claims description 6
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 claims description 6
- 229960003237 betaine Drugs 0.000 claims description 6
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 claims description 6
- FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 claims description 5
- 229920000259 polyoxyethylene lauryl ether Polymers 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- LJINSKIHVMGTDJ-UHFFFAOYSA-N 2-(2,2-diaminoethylamino)acetic acid Chemical compound NC(N)CNCC(O)=O LJINSKIHVMGTDJ-UHFFFAOYSA-N 0.000 claims 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 300
- 102000007330 LDL Lipoproteins Human genes 0.000 description 300
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 50
- 102000015439 Phospholipases Human genes 0.000 description 50
- 108010064785 Phospholipases Proteins 0.000 description 50
- 108010028554 LDL Cholesterol Proteins 0.000 description 34
- 108010017342 very high density lipoproteins Proteins 0.000 description 31
- 102000015779 HDL Lipoproteins Human genes 0.000 description 30
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 30
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 29
- 241000047703 Nonion Species 0.000 description 17
- 230000009257 reactivity Effects 0.000 description 12
- 239000000852 hydrogen donor Substances 0.000 description 11
- 238000002835 absorbance Methods 0.000 description 10
- 239000002245 particle Substances 0.000 description 10
- 108010023417 cholesterol dehydrogenase Proteins 0.000 description 9
- 108010085346 steroid delta-isomerase Proteins 0.000 description 9
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 8
- 230000008030 elimination Effects 0.000 description 8
- 238000003379 elimination reaction Methods 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 150000003905 phosphatidylinositols Chemical class 0.000 description 7
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 6
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 6
- 206010003210 Arteriosclerosis Diseases 0.000 description 6
- 208000011775 arteriosclerosis disease Diseases 0.000 description 6
- 229920000447 polyanionic polymer Polymers 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 201000001320 Atherosclerosis Diseases 0.000 description 5
- 108090000553 Phospholipase D Proteins 0.000 description 5
- 150000001448 anilines Chemical class 0.000 description 5
- 150000001768 cations Chemical class 0.000 description 5
- 150000003904 phospholipids Chemical class 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000005199 ultracentrifugation Methods 0.000 description 5
- 239000004471 Glycine Substances 0.000 description 4
- 108010013563 Lipoprotein Lipase Proteins 0.000 description 4
- 102100022119 Lipoprotein lipase Human genes 0.000 description 4
- 102000014384 Type C Phospholipases Human genes 0.000 description 4
- 108010079194 Type C Phospholipases Proteins 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 4
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 4
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 4
- 102100031415 Hepatic triacylglycerol lipase Human genes 0.000 description 3
- 102100037611 Lysophospholipase Human genes 0.000 description 3
- 108020002496 Lysophospholipase Proteins 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
- 102000011420 Phospholipase D Human genes 0.000 description 3
- 108010058864 Phospholipases A2 Proteins 0.000 description 3
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 3
- 125000005037 alkyl phenyl group Chemical group 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000000593 degrading effect Effects 0.000 description 3
- 238000006911 enzymatic reaction Methods 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 230000036210 malignancy Effects 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 229920001983 poloxamer Polymers 0.000 description 3
- 235000002639 sodium chloride Nutrition 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 241000193755 Bacillus cereus Species 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 108010046315 IDL Lipoproteins Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 229960000633 dextran sulfate Drugs 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 150000002327 glycerophospholipids Chemical class 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- IYDGMDWEHDFVQI-UHFFFAOYSA-N phosphoric acid;trioxotungsten Chemical compound O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.OP(O)(O)=O IYDGMDWEHDFVQI-UHFFFAOYSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 101710139410 1-phosphatidylinositol phosphodiesterase Proteins 0.000 description 1
- AOTXQRRUWFSXCN-UHFFFAOYSA-N 3-(3,5-dimethoxyanilino)-2-hydroxypropane-1-sulfonic acid Chemical compound COC1=CC(NCC(O)CS(O)(=O)=O)=CC(OC)=C1 AOTXQRRUWFSXCN-UHFFFAOYSA-N 0.000 description 1
- DYPGTLUYQZIULN-UHFFFAOYSA-N 3-(3-methoxy-5-methylanilino)propane-1-sulfonic acid Chemical compound COC1=CC(C)=CC(NCCCS(O)(=O)=O)=C1 DYPGTLUYQZIULN-UHFFFAOYSA-N 0.000 description 1
- CDGBQMHYFARRCC-UHFFFAOYSA-N 3-(n-ethyl-3,5-dimethylanilino)-2-hydroxypropane-1-sulfonic acid Chemical compound OS(=O)(=O)CC(O)CN(CC)C1=CC(C)=CC(C)=C1 CDGBQMHYFARRCC-UHFFFAOYSA-N 0.000 description 1
- IBSUMVZKDLDAEK-UHFFFAOYSA-N 3-(n-ethyl-3-methylanilino)propane-1-sulfonic acid Chemical compound OS(=O)(=O)CCCN(CC)C1=CC=CC(C)=C1 IBSUMVZKDLDAEK-UHFFFAOYSA-N 0.000 description 1
- NYLUYMWPXIIXDX-UHFFFAOYSA-N 3-(phenylazaniumyl)propane-1-sulfonate Chemical compound OS(=O)(=O)CCCNC1=CC=CC=C1 NYLUYMWPXIIXDX-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 108010004103 Chylomicrons Proteins 0.000 description 1
- 235000001258 Cinchona calisaya Nutrition 0.000 description 1
- 241001191009 Gymnomyza Species 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 101000847066 Homo sapiens Translin-associated protein X Proteins 0.000 description 1
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 1
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101710161551 Pectate lyase 3 Proteins 0.000 description 1
- 102100026918 Phospholipase A2 Human genes 0.000 description 1
- 101710096328 Phospholipase A2 Proteins 0.000 description 1
- 101710124951 Phospholipase C Proteins 0.000 description 1
- 229920002025 Pluronic® F 88 Polymers 0.000 description 1
- 229920002057 Pluronic® P 103 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 101710179609 Probable pectin lyase C Proteins 0.000 description 1
- 102100037097 Protein disulfide-isomerase A3 Human genes 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 102100032834 Translin-associated protein X Human genes 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 230000000923 atherogenic effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 150000001840 cholesterol esters Chemical class 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 239000000701 coagulant Substances 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical class C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- DDXLVDQZPFLQMZ-UHFFFAOYSA-M dodecyl(trimethyl)azanium;chloride Chemical compound [Cl-].CCCCCCCCCCCC[N+](C)(C)C DDXLVDQZPFLQMZ-UHFFFAOYSA-M 0.000 description 1
- 238000010799 enzyme reaction rate Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000000497 foam cell Anatomy 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000011544 gradient gel Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- INHCSSUBVCNVSK-UHFFFAOYSA-L lithium sulfate Inorganic materials [Li+].[Li+].[O-]S([O-])(=O)=O INHCSSUBVCNVSK-UHFFFAOYSA-L 0.000 description 1
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 1
- 239000011654 magnesium acetate Substances 0.000 description 1
- 235000011285 magnesium acetate Nutrition 0.000 description 1
- 229940069446 magnesium acetate Drugs 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000011147 magnesium chloride Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 239000011565 manganese chloride Substances 0.000 description 1
- 235000002867 manganese chloride Nutrition 0.000 description 1
- 229940099607 manganese chloride Drugs 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920001992 poloxamer 407 Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000007686 potassium Nutrition 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229960000948 quinine Drugs 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 108091008012 small dense LDL Proteins 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- SVLRFMQGKVFRTB-UHFFFAOYSA-M sodium;3-(3,5-dimethoxyanilino)-2-hydroxypropane-1-sulfonate Chemical compound [Na+].COC1=CC(NCC(O)CS([O-])(=O)=O)=CC(OC)=C1 SVLRFMQGKVFRTB-UHFFFAOYSA-M 0.000 description 1
- HLXGRHNZZSMNRX-UHFFFAOYSA-M sodium;3-(n-ethyl-3,5-dimethylanilino)-2-hydroxypropane-1-sulfonate Chemical compound [Na+].[O-]S(=O)(=O)CC(O)CN(CC)C1=CC(C)=CC(C)=C1 HLXGRHNZZSMNRX-UHFFFAOYSA-M 0.000 description 1
- IRQRBVOQGUPTLG-UHFFFAOYSA-M sodium;3-(n-ethyl-3-methylanilino)-2-hydroxypropane-1-sulfonate Chemical compound [Na+].[O-]S(=O)(=O)CC(O)CN(CC)C1=CC=CC(C)=C1 IRQRBVOQGUPTLG-UHFFFAOYSA-M 0.000 description 1
- ZPCAZHPYLUKSMY-UHFFFAOYSA-M sodium;3-(n-ethyl-3-methylanilino)-2-hydroxypropane-1-sulfonate;dihydrate Chemical compound O.O.[Na+].[O-]S(=O)(=O)CC(O)CN(CC)C1=CC=CC(C)=C1 ZPCAZHPYLUKSMY-UHFFFAOYSA-M 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- RBTVSNLYYIMMKS-UHFFFAOYSA-N tert-butyl 3-aminoazetidine-1-carboxylate;hydrochloride Chemical compound Cl.CC(C)(C)OC(=O)N1CC(N)C1 RBTVSNLYYIMMKS-UHFFFAOYSA-N 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/60—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving cholesterol
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Claims (12)
1
1. Fremgangsmåde til kvantitativt at bestemme lille, tæt LDL-kolesterol i en prøve, omfattende trinnene: (1) at eliminere kolesterol i LDL andet end lille, tæt LDL i tilstedeværelsen af sphingomyelinase, og derefter (2) kvantitativt at bestemme kolesterol i den resterende lille, tætte LDL.
2. Fremgangsmåden til kvantitativt at bestemme lille, tæt LDL-kolesterol ifølge krav 1 , hvor koncentrationen af sphingomyelinase som skal anvendes i trin (1) er i området fra 0,1 U/mL til 100 U/mL.
3. Fremgangsmåden til kvantitativt at bestemme lille, tæt LDL-kolesterol ifølge et hvilket som helst af kravene 1 til 2, hvor et enzym til kolesterolmåling tilsættes i tilstedeværelsen af overfladeaktivt stofsom er polyoxyethylen-polyoxypropylen copolymer, eller et polyoxyethylen-nonylphenylæter eller polyoxyethylen-alkylæter som virker på mindst lille, tæt LDL, i trin (2), hvor HLB af det overfladeaktive stof er 11 eller mere og mindre end 14.
4. Fremgangsmåden til kvantitativt at bestemme lille, tæt LDL-kolesterol ifølge et hvilket som helst af kravene 1 til 3, yderligere omfattende trin (a) at eliminere kolesterol i lipoproteiner andre end LDL i en prøve i tilstedeværelsen af kolesterolesterase, som udføres før trin (2), men samtidigt med, før, eller efter trin (1).
5. Fremgangsmåden til kvantitativt at bestemme lille, tæt LDL-kolesterol ifølge krav 4, hvor koncentrationen af kolesterolesterase som skal anvendes i trin (a) er i området fra 0,01 U/mL til 10 U/mL.
6. Fremgangsmåden til kvantitativt at bestemme lille, tæt LDL-kolesterol ifølge krav 4 eller 5, hvor et overfladeaktivt stof som virker på lipoproteiner andre end LDL som er overfladeaktivt stof valgt fra gruppen bestående af polyoxyethylen-laurylæter, polyoxyethylen-cetylæter, polyoxyethylen-oleylæter, og polyoxyethylen-alkylphenylæter yderligere tilsættes i trin (a), hvor HLB af det overfladeaktive stof er 13 eller mere og mindre end 15. 2
7. Fremgangsmåden til kvantitativt at bestemme lille, tæt LDL-ko I este ro I ifølge krav 6, hvor koncentrationen af det overfladeaktive stofsom skal anvendes i trin (a) er i området fra 0,05% til 1,0%.
8. Fremgangsmåden til kvantitativt at bestemme lille, tæt LDL-ko I este ro I ifølge et hvilket som helst af kravene 4 til 7, hvor kolesteroloxidase, og katalase yderligere tilsættes i trin (a).
9. Fremgangsmåden til kvantitativt at bestemme lille, tæt LDL-kolesterol ifølge et hvilket som helst af kravene 4 til 7, hvor kolesteroloxidase og 4-aminoantipyrin yderligere tilsættes i trin (a).
10. Fremgangsmåden til kvantitativt at bestemme lille, tæt LDL-kolesterol ifølge et hvilket som helst af kravene 4 til 9, hvor reaktionen i trin (a) og reaktionen i trin (1) udføres samtidigt i den samme opløsning.
11. Fremgangsmåden til kvantitativt at bestemme lille, tæt LDL-kolesterol ifølge et hvilket som helst af kravene 4 til 10, hvor det overfladeaktive stof som er et ikke-ionisk overfladeaktivt stof valgt fra gruppen bestående af a polyoxyethylen-laurylæter, polyoxyethylen-cetylæter, polyoxyethylen-oleylæter, polyoxyethylen-alkylphenylæter, polyoxyethylen-alkylæter, polyoxyethylen-alkylphenylæter, og polyoxyethylen-alkylamin; et anionisk overfladeaktivt stof valgt fra gruppen bestående af polyoxyethylen-alkylætersulfat, alkylsulfat, amidætersulfat, og alkyltaurat; et kationisk overfladeaktivt stofvalgt fra gruppen bestående af et alkylmethylammoniumsalt, og et kvarternært ammoniumsalt; eller et amfoterisk overfladeaktivt stof valgt fra gruppen bestående af laurylbetain, dimethylalkylbetain, og natriumalkyldiaminoethylglycin yderligere tilsættes i trin (a).
12. Kit til kvantitativt at bestemme lille, tæt LDL-kolesterol, indeholdende mindst de følgende to typer af reagenssammensætning: (i) en reagenssammensætning indeholdende mindst sphingomyelinase; (ii) en reagenssammensætning indeholdende: et overfladeaktivt stof som er en polyoxyethylen-polyoxypropylen copolymer, eller et polyoxyethylen-nonylphenylæter eller 3 polyoxyethylen-alkylæter, hvor HLB af det overfladeaktive stof er 11 eller mere og mindre end 14; 4-aminoantipyrin; og peroxidase. L3. Kittet til kvantitativt at bestemme lille, tæt LDL-ko I este ro I, ifølge krav 12 ndeholdende mindst 3 reagenssammensætninger, som yderligere indeholder (iii) sn reagenssammensætning indeholdende: et ikke-ionisk overfladeaktivt stofvalgt ra gruppen bestående eller mindst en polyoxyethylen-laurylæter, polyoxyethylen-:etylæter, polyoxyethylen-oleylæter, polyoxyethylen-alkylphenylæter, Dolyoxyethylen-alkylæter, polyoxyethylen-alkylphenylæter, og polyoxyethylen-alkylamin; et anionisk overfladeaktivt stofvalgt fra gruppen bestående af Dolyoxyethylen-alkylætersulfat, alkylsulfat, amidætersulfat, og alkyltaurat; et cationisk overfladeaktivt stof valgt fra gruppen bestående af et alkylmethylammoniumsalt, og et kvarternært ammoniumsalt; eller et amfoterisk Dverfladeaktivt stof valgt fra gruppen bestående af laurylbetain, jimethylalkylbetain, og natriumalkyldiaminoethylglycin. L4. Kittet til kvantitativt at bestemme lille, tæt LDL-ko I este ro I ifølge krav 12, hvor eagenssammensætningen (i) yderligere indeholder: et ikke-ionisk overfladeaktivt stofvalgt fra gruppen bestående af mindst en polyoxyethylen-laurylæter, polyoxyethylen-cetylæter, polyoxyethylen-oleylæter, polyoxyethylen-alkylphenylæter, polyoxyethylen-alkylæter, polyoxyethylen-alkylphenylæter, og polyoxyethylen-alkylamin; et anionisk overfladeaktivt stofvalgt fra gruppen bestående af polyoxyethylen-alkylætersulfat, alkylsulfat, amidætersulfat, og alkyltaurat; et kationisk overfladeaktivt stof valgt fra gruppen bestående af et alkylmethylammoniumsalt, og et kvarternært ammoniumsalt; eller et amfoterisk overfladeaktivt stof valgt fra gruppen bestående af laurylbetain, dimethylalkylbetain, og natriumalkyldiaminoethylglycin.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2007264908 | 2007-10-10 | ||
| PCT/JP2008/068489 WO2009048143A1 (ja) | 2007-10-10 | 2008-10-10 | small,dense LDLコレステロールの定量方法およびキット |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2208794T3 true DK2208794T3 (da) | 2016-06-06 |
Family
ID=40549287
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK08837388.1T DK2208794T3 (da) | 2007-10-10 | 2008-10-10 | Fremgangsmåde og kit til kvantificering af lille, tæt LDL-kolesterol |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US8440419B2 (da) |
| EP (1) | EP2208794B1 (da) |
| JP (1) | JP5450080B2 (da) |
| KR (1) | KR101586505B1 (da) |
| CN (2) | CN103952462B (da) |
| AU (1) | AU2008311676B2 (da) |
| CA (1) | CA2702172C (da) |
| DK (1) | DK2208794T3 (da) |
| WO (1) | WO2009048143A1 (da) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011136316A1 (ja) * | 2010-04-30 | 2011-11-03 | 協和メデックス株式会社 | 低密度リポ蛋白中のコレステロールの測定方法、測定用試薬及び測定用キット |
| US9151768B2 (en) * | 2010-07-23 | 2015-10-06 | Denka Seiken Co., Ltd. | Method for quantifying the amount of cholesterol in high-density lipoprotein 3 |
| US20130171674A1 (en) * | 2010-07-23 | 2013-07-04 | Denka Seiken Co., Ltd. | Method for quantifying the amount of cholesterol in high-density lipoprotein 3 |
| CN103080748B (zh) * | 2010-07-23 | 2015-05-27 | 电化生研株式会社 | 高密度脂蛋白3中的胆固醇的定量方法 |
| DK2682476T3 (da) * | 2011-02-28 | 2017-04-24 | Denka Seiken Kk | Fremgangsmåde til kvantificering af kolesterol i højdensitetslipoprotein 2 og anvendelse af et reagenskit til fremgangsmåden |
| CA2842893C (en) * | 2011-07-29 | 2019-03-05 | Kyowa Medex Co., Ltd. | Sphingomyelin measurement method and measurement kit |
| KR102381248B1 (ko) | 2011-11-11 | 2022-04-01 | 엑시스-시일드 에이에스 | 혈액 샘플 분석 방법 |
| JP5996234B2 (ja) * | 2012-03-30 | 2016-09-21 | デンカ生研株式会社 | 免疫分析方法及び試薬 |
| JP5834134B2 (ja) * | 2012-03-30 | 2015-12-16 | 積水メディカル株式会社 | 血液試料中の物質の測定法 |
| KR20160091276A (ko) | 2015-01-23 | 2016-08-02 | 바디텍메드(주) | Cdc 단백질 및 콜레스테롤 항체를 이용한 콜레스테롤 측정 방법 |
| WO2016117956A1 (ko) * | 2015-01-23 | 2016-07-28 | 바디텍메드(주) | Cdc 단백질 및 콜레스테롤 항체를 이용한 콜레스테롤 측정 방법 |
| CN104673879A (zh) * | 2015-03-07 | 2015-06-03 | 王贤俊 | 一种小而密低密度脂蛋白胆固醇检测试剂盒及其制备 |
| CN107446989B (zh) * | 2017-06-23 | 2020-07-14 | 美康生物科技股份有限公司 | 测定样本中的小而密低密度脂蛋白胆固醇的方法及试剂 |
| CN107287277B (zh) * | 2017-06-23 | 2020-01-07 | 美康生物科技股份有限公司 | 小而密低密度脂蛋白胆固醇检测试剂盒 |
| JP7134667B2 (ja) | 2018-03-28 | 2022-09-12 | デンカ株式会社 | リポ蛋白コレステロールの定量方法、定量試薬及び定量キット |
| CN109837270B (zh) * | 2018-06-19 | 2022-09-09 | 深圳市安帝宝科技有限公司 | 一种使肌醇脱氢酶、酮胺氧化酶和鞘磷脂酶在液体中长期稳定的方法 |
| JP7029139B2 (ja) | 2018-08-23 | 2022-03-03 | デンカ株式会社 | 非アルコール性脂肪性肝炎の検出を補助する方法 |
| CN111398607B (zh) * | 2019-01-03 | 2024-02-23 | 中元汇吉生物技术股份有限公司 | 一种小而密低密度脂蛋白胆固醇测定试剂 |
| CN110160974A (zh) * | 2019-05-28 | 2019-08-23 | 天津悦和康生物技术有限公司 | 一种检测小而密低密度脂蛋白胆固醇的试剂盒 |
| JP7396965B2 (ja) * | 2019-09-10 | 2023-12-12 | デンカ株式会社 | ｓｍａｌｌ，ｄｅｎｓｅ ＬＤＬコレステロールの定量方法およびキット |
| JP6703175B1 (ja) | 2019-09-10 | 2020-06-03 | デンカ生研株式会社 | キットおよび方法 |
| JP6869300B2 (ja) | 2019-09-10 | 2021-05-12 | デンカ株式会社 | ｓｍａｌｌ，ｄｅｎｓｅ ＬＤＬコレステロールの定量方法およびキット |
| JP7427522B2 (ja) * | 2019-09-10 | 2024-02-05 | デンカ株式会社 | キットおよび方法 |
| CN110791549B (zh) * | 2019-12-03 | 2023-09-26 | 宁波普瑞柏生物技术股份有限公司 | 定量测定小而密低密度脂蛋白胆固醇的方法和试剂盒 |
| CN111269962B (zh) * | 2020-03-18 | 2021-03-23 | 浙江夸克生物科技有限公司 | 一种小而密低密度脂蛋白胆固醇测定试剂盒及其应用 |
| JP7437239B2 (ja) * | 2020-06-02 | 2024-02-22 | デンカ株式会社 | リポ蛋白コレステロールの定量方法およびキット |
| CN111551512B (zh) * | 2020-06-11 | 2023-07-25 | 安徽大千生物工程有限公司 | 一种高灵敏度和特异度的sdLDL-C比色法检测试剂盒及其制备使用方法 |
| JP7437263B2 (ja) * | 2020-07-31 | 2024-02-22 | デンカ株式会社 | 試薬組成物およびキット |
| WO2023049473A1 (en) * | 2021-09-27 | 2023-03-30 | Icahn School Of Medicine At Mount Sinai | System and method to determine the concentration of lipoprotein (a) cholesterol |
| WO2023079599A1 (ja) * | 2021-11-02 | 2023-05-11 | デンカ株式会社 | 試薬組成物およびキット |
| CN113913492A (zh) * | 2021-11-08 | 2022-01-11 | 东软威特曼生物科技(南京)有限公司 | 一种小而密低密度脂蛋白胆固醇检测试剂盒及其制备方法 |
| CN114214389B (zh) * | 2022-02-21 | 2022-07-12 | 北京沃森赛瑟生物技术有限公司 | 脂蛋白胆固醇检测方法和试剂盒 |
| US20250327111A1 (en) * | 2022-04-11 | 2025-10-23 | Denka Company Limited | Reagent composition and kit |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4456715B2 (ja) * | 2000-02-28 | 2010-04-28 | 協和メデックス株式会社 | レムナント様リポ蛋白中のコレステロールの測定方法および測定試薬 |
| JP4593026B2 (ja) | 2001-07-18 | 2010-12-08 | 栄研化学株式会社 | ＳｍａｌｌｄｅｎｓｅＬＤＬの測定方法 |
| WO2004053500A1 (ja) | 2002-12-06 | 2004-06-24 | Denka Seiken Co., Ltd. | 小粒子低比重リポ蛋白の定量法 |
| JP4647927B2 (ja) * | 2004-03-31 | 2011-03-09 | デンカ生研株式会社 | 低密度リポ蛋白中コレステロールのマルチ定量法 |
| TWI379904B (en) | 2005-02-14 | 2012-12-21 | Kyowa Medex Co Ltd | A method for quantifying cholesterol of remnant-like particles lipoprotein, reagent and kit |
| TWI372783B (en) | 2005-04-27 | 2012-09-21 | Kyowa Medex Co Ltd | A process for measuring the cholesterol in high density lipoprotein |
| DE602006018035D1 (de) * | 2005-08-31 | 2010-12-16 | Denka Seiken Kk | Verfahren und kit zur quantitativen bestimmung von small, dense ldl cholesterol |
| JP4790464B2 (ja) | 2006-03-28 | 2011-10-12 | 富士通株式会社 | 業務分析システム |
| JP5081814B2 (ja) | 2006-05-01 | 2012-11-28 | デンカ生研株式会社 | 家族性複合型高脂血症の検出方法 |
| DE602007012455D1 (de) | 2006-10-18 | 2011-03-24 | Kyowa Medex Co Ltd | Verfahren zur quantifizierung von cholesterin in kleinem dichtem low-density-lipoprotein |
| KR101394802B1 (ko) | 2007-02-28 | 2014-05-15 | 덴카 세이켄 가부시키가이샤 | 소립자 저비중 리포 단백의 정량 시약 |
-
2008
- 2008-10-10 KR KR1020107010164A patent/KR101586505B1/ko active Active
- 2008-10-10 DK DK08837388.1T patent/DK2208794T3/da active
- 2008-10-10 CN CN201410058250.0A patent/CN103952462B/zh active Active
- 2008-10-10 EP EP08837388.1A patent/EP2208794B1/en active Active
- 2008-10-10 US US12/682,240 patent/US8440419B2/en active Active
- 2008-10-10 AU AU2008311676A patent/AU2008311676B2/en active Active
- 2008-10-10 JP JP2009537043A patent/JP5450080B2/ja active Active
- 2008-10-10 CN CN200880121086.6A patent/CN101896620B/zh active Active
- 2008-10-10 CA CA2702172A patent/CA2702172C/en active Active
- 2008-10-10 WO PCT/JP2008/068489 patent/WO2009048143A1/ja not_active Ceased
-
2013
- 2013-04-10 US US13/860,435 patent/US8865423B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2702172C (en) | 2018-04-24 |
| WO2009048143A1 (ja) | 2009-04-16 |
| CN103952462B (zh) | 2017-10-24 |
| EP2208794B1 (en) | 2016-04-27 |
| JPWO2009048143A1 (ja) | 2011-02-24 |
| CN101896620B (zh) | 2014-11-26 |
| US8865423B2 (en) | 2014-10-21 |
| AU2008311676B2 (en) | 2014-05-29 |
| US8440419B2 (en) | 2013-05-14 |
| CA2702172A1 (en) | 2009-04-16 |
| EP2208794A4 (en) | 2011-03-30 |
| US20100255516A1 (en) | 2010-10-07 |
| JP5450080B2 (ja) | 2014-03-26 |
| KR101586505B1 (ko) | 2016-01-18 |
| CN103952462A (zh) | 2014-07-30 |
| EP2208794A1 (en) | 2010-07-21 |
| CN101896620A (zh) | 2010-11-24 |
| KR20100091176A (ko) | 2010-08-18 |
| AU2008311676A1 (en) | 2009-04-16 |
| US20130288281A1 (en) | 2013-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2208794T3 (da) | Fremgangsmåde og kit til kvantificering af lille, tæt LDL-kolesterol | |
| KR101394802B1 (ko) | 소립자 저비중 리포 단백의 정량 시약 | |
| JP5548733B2 (ja) | 小粒子低比重リポ蛋白の定量方法および定量キット | |
| US8906638B2 (en) | Method for quantification of remnant-like lipoprotein cholesterol and kit for same | |
| WO2012011563A1 (ja) | 高密度リポタンパク質３中のコレステロールの定量方法 | |
| TWI731088B (zh) | 富含三酸甘油酯脂蛋白中之膽固醇之定量方法 |